ANGO

Rating buyAI Memo

AngioDynamics

As of 2026-04-03/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-04-03 • Model: RankAlpha Sentiment AI

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

buy

Confidence

medium

Horizon

—

Key catalyst

Fiscal 2026 year-end procedure volumes & margins (FY end 2026-05-31) • 2026-07-31

Expected move: +52%

Biggest risk

If procedure volumes remain soft or integration costs persist, near-term working-capital swings and margin pressure could push the stock below current levels and compress multiples.

Invalidation

Break below $9 or thesis failure.

What would change my mind?

If restructuring and acquisition synergies materialize as outlined in the 2025 10-K and procedure volumes recover, AngioDynamics can re-rate toward the analyst high as margins expand and cash conversion improves.

Research note

Recommendation

buy

Confidence

medium

As of

2026-04-03

Base target

$18

p=55%

Bull target

$24

p=25%

Bear target

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Near-term results volatility from procedure mix and working-capital swings
Realization of restructuring and acquisition synergies
If restructuring and acquisition synergies materialize as outlined in the 2025 10-K and procedure volumes recover, AngioDynamics can re-rate toward the analyst high as margins expand and cash conversion improves.

BearKey bullets

Integration costs from acquisitions exceeding projections
Reimbursement or hospital purchasing slowdowns
Slower-than-expected procedure-volume recovery

WatchKey bullets

Fiscal 2026 year-end procedure volumes & margins (FY end 2026-05-31)

Summary

High-level snapshot

Recommendation

buy

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $18 (p=55%)

Bull/Bear spread: +109% / -26%

Vs latest close: Bull +109% · Base +52% · Bear -26%

Scenario probabilities

Bull Target: $24 (p=25%)Base Target: $18 (p=55%)Bear Target: $9 (p=20%)

Commentary

Tone in filings and recent releases is cautious but execution-focused; the 10-K flags acquisition/restructuring topics while the 10-Q shows typical quarterly balance-sheet movements, implying mixed near-term sentiment but material upside if cost-savings arrive [#10-K-2025-07-18][#10-Q-2026-04-02].

As of 2026-04-03 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

If procedure volumes remain soft or integration costs persist, near-term working-capital swings and margin pressure could push the stock below current levels and compress multiples.

Drivers

Scannable catalysts and supporting factors

Near-term results volatility from procedure mix and working-capital swings
Realization of restructuring and acquisition synergies

Human Analyst Targets

External snippets for comparison only; verify at source.

Unverified externalLast fetched 2026-04-03Source quality: external scrape

External snippets are unverified; treat as directional signals only. Always confirm with the original provider.

Inline RA est

Provider

serper

Median (USD)

$17.50

Range (USD)

$10.41 - $24.00

Count

Query: AngioDynamics Inc Common (ANGO) analyst consensus price target high low average

ANGO | AngioDynamics Inc. Analyst Estimates & Ratings - WSJ
Search result #8
Stock Price Target ANGO. High, $24.00. Median, $18.00. Low, $16.00. Average, $19.33. Current Price, $10.41. Related Links: Options · Overview · Research & ...
Extracted: $24.00, $18.00, $16.00, $19.33, $10.41Open source
AngioDynamics Stock Forecast & Price Prediction (ANGO)
Search result #3
According to projections from 3 analysts, the average 12-month price target for AngioDynamics is 19.33 USD, with a high estimate of 24 USD and a low estimate of ...
Extracted: $19.33, $24.00Open source
ANGO Stock Forecast: Angiodynamics Inc. Price Predictions for 2026
Search result #5
Based on our analysis of 8 Wall Street analysts, ANGO has a bullish consensus with a median price target of $18.00 (ranging from $16.00 to $24.00). The overall ...
Extracted: $18.00, $16.00, $24.00Open source
ANGO - AngioDynamics Stock - Displayed [76 Analyst Price Targets]
Search result #6
Highest price target for ANGO is $18, Lowest price target is $16, average price target is $17. Most recent stock forecast was given by WILLIAM PLOVANIC from ...
Extracted: $18.00, $16.00, $17.00Open source
AngioDynamics, Inc.: Target Price Consensus and Analysts ...
Search result #7
Stock ANGO ... Average target price. 19.33USD. Spread / Average Target. +77.37%. High Price Target. 24.00USD. Spread / Highest target. +120.18%. Low Price Target.
Extracted: $19.33, $24.00Open source
AngioDynamics, Inc. (ANGO) Stock Price, News, Quote & History
Search result #2
Find the latest AngioDynamics, Inc. (ANGO) stock quote, history, news and other vital information to help you with your stock trading and investing.
Open source

Scenarios

Bull Target (Scenario probability)

$24 / p=25% prob

Base Target (Scenario probability)

$18 / p=55% prob

Bear Target (Scenario probability)

$9 / p=20% prob

Price $11 as of 2026-05-29

Nearest Scenario: Bear (∆ 26%)

Targets vs latest close: Bull +109% · Base +52% · Bear -26%

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-07-31
Fiscal 2026 year-end procedure volumes & margins (FY end 2026-05-31)
Procedure-volume recovery and margin progression through FY2026 will be a company-specific driver; investors should watch reported volumes and gross-margin deltas in the FY2026 results window (assume end of reporting period 2026-05-31) as the next clear operating re-rating opportunity [#10-Q-2026-04-02][#10-K-2025-07-18].
Prob 55.00% • Move 18.00% • Priced-in 25.00%

Short-term Catalysts

Next few weeks

Near-term results volatility from procedure mix and working-capital swings
2026-07-31
Quarterly 10-Q disclosures show balance-sheet and working-capital line-item activity that can drive short-term EPS and cash-flow revisions; this raises risk of shorter-term stock weakness around quarterly filings [#10-Q-2026-04-02].
Prob 70% • Move -12% • Priced-in 40%

Long-term Catalysts

Months to a year

Realization of restructuring and acquisition synergies
2026-05-31
Management disclosed acquisition, restructuring and other items in the 2025 Form 10-K; market-visible cost-savings and integration benefits are expected to flow through fiscal 2026 operating results, supporting margin expansion and EPS upside [#10-K-2025-07-18][#10-Q-2026-04-02].
Prob 60% • Move 25% • Priced-in 30%

Risks

Integration costs from acquisitions exceeding projections
Reimbursement or hospital purchasing slowdowns
Slower-than-expected procedure-volume recovery
Working-capital swings that pressure quarterly EPS

Peers

Symbol	Summary
AVNS	Avanos — comparable mid-cap medtech with similar hospital exposure and procedure-driven revenue cycles; useful comparator for recovery and reimbursement sensitivity.
OFIX	Orthofix — device-focused, hospital-distributed peer with product-rehab and procedure adoption dynamics relevant to execution risk.
SBC	SBC Medical Group — smaller device peer; comparable exposure to surgical/hospital procedure demand and supply-chain sensitivity.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment AI
Human targets: serper
Targets query: AngioDynamics Inc Common (ANGO) analyst consensus price target high low average
Analysis date: 2026-04-03

AI Stock Memo: ANGO - AngioDynamics - RankAlpha